

AMENDMENTS TO THE CLAIMS

Please amend claims 20-23 and 36 as follows.

Please cancel claim 35.

Listing of Claims

Claims 1-19 (canceled)

Claim 20 (currently amended): A method ~~of for~~ detecting ~~the presence~~ binding of an antibody that specifically reacts with an Fkh^{sf} polypeptide that comprises the amino acid sequence set forth in SEQ ID NO:2 ~~in a biological sample~~, said method comprising the steps of:

(a) contacting ~~said a~~ biological sample with an antibody, or an antibody fragment thereof, that specifically binds to an Fkh^{sf} polypeptide that comprises the amino acid sequence set forth in SEQ ID NO:2, under conditions that allow binding of said antibody or antibody fragment to the Fkh^{sf} polypeptide; and

(b) detecting binding of the antibody, or antibody fragment thereof, ~~to the~~ Fkh^{sf} polypeptide.

Claim 21 (currently amended): The method of ~~any one of either~~ claims claim 20, ~~35- or claim 36~~ wherein said antibody is selected from the group consisting of:

- (a) polyclonal antibody,
- (b) a murine monoclonal antibody,
- (c) a humanized antibody derived from (b), and
- (d) ~~a human monoclonal antibody, and.~~

Claim 22 (currently amended): The method of ~~any one of either~~ claims claim 20, ~~35- or claim 36~~, wherein said antibody fragment is selected from the group consisting of F(ab')₂, F(ab)₂, Fab', Fab, Fv, sFv, and minimal recognition unit.

Claim 23 (currently amended): The method of ~~any one of either claims claim 20, 35- or claim 36~~, wherein said antibody or said antibody fragment further comprises a detectable label selected from the group consisting of radioisotope, fluorescent label, chemiluminescent label, enzyme label, bioluminescent label, and colloidal gold.

Claims 24-35 (canceled)

Claim 36. (currently amended): A method for detecting ~~the presence of a mutant Fkh^{sf} polypeptide in a biological sample~~ binding of an antibody that specifically reacts with a mutant Fkh^{sf} polypeptide, said mutant Fkh^{sf} polypeptide being encoded by a polynucleotide comprising (i) the sequence set forth in SEQ ID NO:1 and (ii) an insertion of the complement of a TT dinucleotide into a region of SEQ ID NO:1, said region comprising the complement of the sequence set forth in SEQ ID NO:11, and said insertion resulting in the complement of the sequence set forth in SEQ ID NO:12, said method comprising the steps of:

(a) contacting ~~the a~~ biological sample with an antibody, or an antibody fragment thereof, that specifically binds to a mutant Fkh^{sf} polypeptide encoded by a polynucleotide comprising (i) the sequence set forth in SEQ ID NO:1 and (ii) an insertion of the complement of a TT dinucleotide into a region of SEQ ID NO:1, said region comprising the complement of the sequence set forth in ~~SEQ ID NO:12~~ SEQ ID NO:11, and said insertion resulting in the complement of the sequence set forth in SEQ ID NO:12, under conditions that allow binding of the antibody or antibody fragment to the mutant Fkh^{sf} polypeptide, and

(b) detecting binding of the antibody, or antibody fragment thereof, ~~to the mutant Fkh^{sf} polypeptide.~~